RPI MN
Alternative Names: pepteron; RPI-MNLatest Information Update: 28 Feb 2025
At a glance
- Originator ReceptoPharm
- Developer Bio Therapeutics; ReceptoPharm
- Class Antiretrovirals; Cobra neurotoxin proteins
- Mechanism of Action Nicotinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Herpes simplex virus infections; HIV infections; Ocular herpes simplex
- Discontinued Rabies; Viral infections
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Amyotrophic-lateral-sclerosis in USA (IM, Injection)
- 28 Feb 2025 No recent reports of development identified for phase-I development in HIV-infections in USA (PO)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Ocular herpes simplex in USA (IM, Injection)